Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof

US8981061B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Marco Colonna · Chesterfield, US
• Axel Bouchon · Kleinmachnow, DE
• Rune Salbo · Copenhagen, DK
• Charlotte Wiberg · Bjärred, SE
• Vibeke Westphal Stennicke · Kokkedal, DK
• Anette Henriksen · Ringe, DK
• Mette Dahl Andersen

Key dates

• Filing date: Nov 30, 2012
• Grant date: Mar 17, 2015
• Expiry date: Nov 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.